XOMA (US) LLC Completes Enrollment in Phase 2 Proof-of-Concept Gevokizumab Trial in Patients With Erosive Osteoarthritis of the Hand

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BERKELEY, Calif., July 22, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today confirmed it has completed patient enrollment in the Company's Phase 2 proof-of-concept (POC) study designed to evaluate the potential for gevokizumab to improve pain symptoms, physical function and structural abnormalities in patients with active inflammatory, erosive osteoarthritis of the hand (EOA) and elevated C-reactive protein (CRP) levels.

Help employers find you! Check out all the jobs and post your resume.

Back to news